Small-Cell Lung Cancer Comorbid with Pulmonary Mycobacterium avium Infection: A Case Report

Chemotherapy ◽  
2018 ◽  
Vol 63 (5) ◽  
pp. 257-261
Author(s):  
Masahiro Yamasaki ◽  
Kunihiko Funaishi ◽  
Naomi Saito ◽  
Ken-ichi Sakamoto ◽  
Sayaka Ishiyama ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Mycobacterium Avium ◽  
Cell Lung Cancer ◽  
Left Lung ◽  
Small Cell ◽  
Mediastinal Lymphadenopathy ◽  
Small Cell Lung ◽  
Before And After ◽  
Avium Infection

Background: Small-cell lung cancer (SCLC) rarely coexists with pulmonary Mycobacterium avium intracellular complex (MAC) infection. The key drug for SCLC treatment is etoposide, which is metabolized by cytochrome P-450 (CYP) 3A4. Meanwhile, the key drugs for pulmonary MAC infection are clarithromycin (CAM) and rifampicin (RFP), and their metabolism influences CYP3A4. Therefore, treatment of concurrent SCLC and pulmonary MAC infection is difficult, and to the best of our knowledge, no report of treatments for concurrent SCLC and pulmonary MAC infection has been published. Patient Concerns and Diagnoses: A 65-year-old man presented to our hospital with abnormal findings of chest computed tomography: (1) a hilar region nodule in the left lung and mediastinal lymphadenopathy and (2) a thick-walled cavity lesion in the right upper lobe of the lung. After further examinations, the former lesions were diagnosed as SCLC, cT4N3M0, stage IIIC and the latter as pulmonary MAC infection, fibrocavitary disease. Interventions and Outcomes: Concurrent treatment was conducted with discontinuation of CAM and RFP before and after etoposide administration. Specifically, intravenous cisplatin and etoposide were administered on day 1 and days 1–3, respectively, and CAM, RFP, and ethambutol (EB) were administered orally on days 6–22 every 4 weeks. Concurrent radiotherapy was added to the drug administration on days 1–27 of the first cycle. The chemotherapy was continued for 4 cycles, followed by continuation of CAM and RFP administration. EB was discontinued because of optic nerve disorder. The treatments were conducted completely and safely, and both of the SCLC lesions and the MAC lesion were improved. Conclusions: Treatments for concurrent SCLC and pulmonary MAC infection may be successfully conducted with discontinuation of CAM and RFP before and after etoposide administration.

Usefulness of CT Chest in Determining Clinically Significant Mediastinal Lymphadenopathy in Patients With Non-Small Cell Lung Cancer (NSCLC)

CHEST Journal ◽  
2003 ◽  
Vol 124 (4) ◽  
pp. 194S
Author(s):  
Mazen Alakhras ◽  
Geetha Kanajam ◽  
Damodhar Nerella ◽  
Karthikeyan Kanagarajan ◽  
Depakkumar Malli ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Mediastinal Lymphadenopathy ◽  
Small Cell Lung ◽  
Clinically Significant

scholarly journals Intramedullary thoracic spinal metastasis from small-cell lung cancer

2013 ◽  
Vol 79 (3-4) ◽  
Author(s):  
S. Katsenos ◽  
M. Nikolopoulou
Keyword(s):  
Lung Cancer ◽  
Spinal Cord ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Spinal Metastasis ◽  
Small Cell ◽  
Mediastinal Lymphadenopathy ◽  
Small Cell Lung ◽  
Intramedullary Spinal Cord ◽  
Thoracic Spinal

Intramedullary thoracic spinal metastasis from small-cell lung cancer. S. Katsenos, M. Nikolopoulou. Lung cancer with intramedullary spinal cord metastasis (ISCM) is a rare event exhibiting dismal prognosis. In the present paper, we describe a 74-year-old male who developed bilateral leg weakness with associated backache and non-productive cough. Chest imaging evaluation demonstrated pronounced bilateral mediastinal lymphadenopathy and a nodular opacity in the right lower lobe. The patient was diagnosed with small cell lung cancer through bronchoscopic procedures. Magnetic resonance imaging of the spinal cord with contrast-enhancement revealed an intramedullary lesion consistent with metastasis at the T5-T6 level. Despite chemotherapy and thoracic spine radiotherapy, he eventually succumbed to the disease 3 months after diagnosis. A brief overview of the current literature is also provided laying emphasis on the therapeutic strategies of this unusual extrathoracic metastatic disease.

scholarly journals Targeted Therapy in Patients With Non–small Cell Lung Cancer Previously Treated With Chemotherapy

Medicina ◽  
2011 ◽  
Vol 47 (9) ◽  
pp. 520 ◽  
Author(s):  
Monika Drobnienė ◽  
Audronė Cicėnienė ◽  
Teresė Želvienė ◽  
Rūta Grigienė ◽  
Nadežda Lachej ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Targeted Therapy ◽  
Small Cell Lung Cancer ◽  
Disease Progression ◽  
Cell Lung Cancer ◽  
Left Lung ◽  
Small Cell ◽  
Prolonged Treatment ◽  
Small Cell Lung ◽  
Cutaneous Toxicity

A case of successful and prolonged treatment of metastatic non–small cell lung cancer with the epidermal growth factor receptor antagonist erlotinib is presented. A never-smoker female was diagnosed with stage IV lung cancer in December 2005. A chest CT scan showed soft tissue mass 35×34 mm in size in the right lung with metastases in the lymph nodes and in the left lung. A biopsy revealed a poorly differentiated adenocarcinoma. The disease showed poor response to the first-line and second-line chemotherapy. Targeted therapy with erlotinib was started in February 2007. The most severe adverse event observed was grade 3 skin rash. The disease was stable until February 2009 when brain metastases were detected. Erlotinib was continued until May 2009 when disease progression in the lungs was confi rmed. The patient died due to ongoing disease progression in December 2009. Retrospective genetic analysis of a tumor specimen was performed, and no mutations in EGFR exons 18–21 were detected. The patient had a significant clinical benefit for the period of 24 months. These results are consistent with previous reports in literature that clinical characteristics such as female gender, nonsmoker, adenocarcinoma histology, and severe cutaneous toxicity seem to predict good response to erlotinib. In the present case, erlotinib proved to be effective even in heavily pretreated, chemotherapy- resistant lung adenocarcinoma. So far, no exact predictive biomarkers of erlotinib effectiveness have been determined; and their further analyses are essential.

scholarly journals Impact of diffusing lung capacity before and after neoadjuvant concurrent chemoradiation on postoperative pulmonary complications among patients with stage IIIA/N2 non-small-cell lung cancer

2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Sumin Shin ◽  
Yong Soo Choi ◽  
Jae Jun Jung ◽  
Yunjoo Im ◽  
Sun Hye Shin ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Pulmonary Complications ◽  
Small Cell ◽  
Postoperative Pulmonary Complication ◽  
Small Cell Lung ◽  
Stage Iiia ◽  
Before And After ◽  
The Impact

Abstract Background and objective This study aims to evaluate the impact of diffusing capacity of the lung for carbon monoxide (DLco) before and after neoadjuvant concurrent chemoradiotherapy (CCRT) on postoperative pulmonary complication (PPC) among stage IIIA/N2 non-small-cell lung cancer (NSCLC) patients. Methods We retrospectively studied 324 patients with stage IIIA/N2 NSCLC between 2009 and 2016. Patients were classified into 4 groups according to DLco before and after neoadjuvant CCRT; normal-to-normal (NN), normal-to-low (NL), low-to-low (LL), and low-to-very low (LVL). Low DLco and very low DLco were defined as DLco < 80% predicted and DLco < 60% predicted, respectively. Results On average, DLco was decreased by 12.3% (±10.5) after CCRT. In multivariable-adjusted analyses, the incidence rate ratio (IRR) for any PPC comparing patients with low DLco to those with normal DLco before CCRT was 2.14 (95% confidence interval (CI) = 1.36–3.36). Moreover, the IRR for any PPC was 3.78 (95% CI = 1.68–8.49) in LVL group compared to NN group. The significant change of DLco after neoadjuvant CCRT had an additional impact on PPC, particularly after bilobectomy or pneumonectomy with low baseline DLco. Conclusions The DLco before CCRT was significantly associated with risk of PPC, and repeated test of DLco after CCRT would be helpful for risk assessment, particularly in patients with low DLco before neoadjuvant CCRT.

scholarly journals NON-SMALL CELL LUNG CANCER PRESENTING AS CAVITARY LESION WITH MYCOBACTERIUM AVIUM ON ACID FAST CULTURE

CHEST Journal ◽  
2020 ◽  
Vol 158 (4) ◽  
pp. A1552
Author(s):  
Jessimar Sanchez ◽  
Anish Samuel ◽  
Aedan McDonough ◽  
Medhat Ismail
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Mycobacterium Avium ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Cavitary Lesion

Prognostic factors before and after recurrence of resected non-small cell lung cancer

2012 ◽  
Vol 50 (4) ◽  
pp. 151-156 ◽  
Author(s):  
Tetsuro Baba ◽  
Hidetaka Uramoto ◽  
Masaru Takenaka ◽  
Yasuhiro Chikaishi ◽  
Soichi Oka ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Prognostic Factors ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Before And After
Sign in / Sign up

Export Citation Format

Share Document